Aerin Medical Company Profile

Background

Overview

Aerin Medical Inc. is a privately held, venture-backed medical technology company headquartered in Mountain View, California. Founded in 2011, the company specializes in developing non-invasive solutions for chronic Ear, Nose, and Throat (ENT) conditions, focusing on nasal airway obstruction and chronic rhinitis. Aerin Medical's mission is to expand access to meaningful relief for millions of patients suffering from these conditions. The company's vision is to change the standard of care for untreated sufferers of ENT conditions by providing safe, practical, and effective innovations that transform how and where patients are treated.

Industry Significance

Aerin Medical has made significant strides in the ENT medical device industry by introducing minimally invasive treatments that offer alternatives to traditional surgical procedures. The company's products have been adopted by numerous ENT physicians, contributing to improved patient outcomes and quality of life. As of March 2026, over 200,000 patients have been treated with Aerin Medical's technologies, underscoring the growing impact of their solutions in the market.

Key Strategic Focus

Core Objectives

Aerin Medical aims to provide ENT physicians with non-invasive solutions that effectively treat chronic nasal conditions, thereby improving patient access to life-changing relief. The company is committed to expanding its market presence and enhancing the adoption of its products among healthcare providers.

Areas of Specialization

The company's primary focus is on developing and commercializing minimally invasive treatments for nasal airway obstruction and chronic rhinitis. These conditions are prevalent and significantly impact patients' quality of life, making effective treatment options highly sought after.

Key Technologies Utilized

Aerin Medical's products leverage proprietary temperature-controlled radiofrequency technology. This technology allows ENT physicians to perform in-office procedures that remodel nasal tissue, providing relief from nasal obstruction and chronic rhinitis without the need for invasive surgery.

Primary Markets Targeted

The company's solutions are primarily targeted at the U.S. market, where nasal airway obstruction affects approximately 20 million Americans. Additionally, chronic rhinitis is a common condition, further expanding the potential patient base for Aerin Medical's products.

Financials and Funding

Total Funds Raised

Aerin Medical has successfully raised a total of $234.92 million across multiple funding rounds.

Recent Funding Rounds

January 2025: The company secured $32.5 million in equity financing, led by major investors including KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group. This funding is intended to support commercial expansion, research and development, and the generation of clinical evidence.

June 2022: Aerin Medical closed a $60 million equity financing led by Ally Bridge Group, with participation from existing investors KCK MedTech, Questa Capital, and OrbiMed. The proceeds are allocated to scaling commercialization efforts and expanding market access.

Notable Investors

The company's investor base includes prominent venture capital and private equity firms such as KCK MedTech, Questa Capital, OrbiMed, Ally Bridge Group, and Ares Management Credit funds.

Utilization of Capital

The funds raised are primarily utilized for:

Scaling commercialization efforts to meet increasing demand from physicians and patients.

Advancing research and development initiatives to enhance existing products and develop new solutions.

Expanding the company's clinical evidence portfolio to support the efficacy and safety of its treatments.

Pipeline Development

Key Pipeline Candidates

Aerin Medical's main products are:

VivAer®: A minimally invasive technology that uses temperature-controlled radiofrequency energy to provide long-term relief from nasal airway obstruction.

RhinAer®: A minimally invasive technology that uses temperature-controlled radiofrequency energy to provide long-term relief from chronic rhinitis.

Stages of Development

Both VivAer and RhinAer have received FDA 510(k) clearance and CE Mark, indicating their safety and efficacy for clinical use. The company continues to conduct clinical studies to further validate and expand the applications of these technologies.

Target Conditions

The primary conditions targeted by Aerin Medical's products are:

Nasal Airway Obstruction: A condition affecting approximately 20 million Americans, characterized by difficulty breathing through the nose due to structural or functional issues.

Chronic Rhinitis: A condition involving inflammation of the nasal mucous membrane, leading to symptoms such as a runny nose, sneezing, and nasal congestion.

Anticipated Milestones

The company aims to achieve the following milestones:

Expand the adoption of VivAer and RhinAer among ENT physicians.

Continue to build a robust clinical evidence portfolio supporting the long-term efficacy of its treatments.

Explore additional indications and applications for its temperature-controlled radiofrequency technology.

Technological Platform and Innovation

Proprietary Technologies

Aerin Medical's proprietary technology involves temperature-controlled radiofrequency energy, which allows for precise remodeling of nasal tissue. This approach provides a non-invasive alternative to traditional surgical interventions, offering patients a safer and more convenient treatment option.

Significant Scientific Methods

The company employs temperature-controlled radiofrequency energy to target specific nasal tissues, enabling effective treatment of nasal airway obstruction and chronic rhinitis. This method is performed in-office under local anesthesia, with minimal downtime for patients.

Leadership Team

Key Executives

Matt Brokaw: President and CEO. Brokaw joined Aerin Medical in 2020, bringing extensive experience in medical device commercialization and strategic growth.

William McClellan: Chief Financial Officer. McClellan oversees the company's financial operations and strategic financial planning.

Andrew Frazier: Vice President of Engineering & Manufacturing Operations. Frazier leads the development and manufacturing of Aerin Medical's products.

Shane Johnson: Vice President of Sales. Johnson is responsible for driving sales strategies and expanding the company's market presence.

Scott Miller: Vice President of Finance & Operations. Miller manages financial planning and operational efficiency within the company.

Scott Smith: General Counsel and Compliance Officer. Smith ensures legal compliance and oversees the company's legal affairs.

Leadership Changes

In 2020, Matt Brokaw was appointed as President and CEO, succeeding Fred Dinger. This leadership change was part of a strategic initiative to accelerate the company's growth and market penetration.

Competitor Profile

Market Insights and Dynamics

The market for non-invasive treatments for chronic nasal conditions is growing, driven by increasing patient demand for alternatives to traditional surgical procedures. Aerin Medical faces competition from other medical device companies offering similar solutions, as well as pharmaceutical companies developing medical therapies for nasal conditions.

Competitor Analysis

Key competitors include:

Impel Pharmaceuticals: A pharmaceutical company developing therapies for central nervous system diseases, including treatments for nasal conditions.

ENvizion: A company developing electromagnetic feeding tube placement navigation technology.

Tian Medical: A company developing medical devices for the treatment of migraine.

Protalex: A clinical-stage biopharmaceutical company focused on developing drugs for autoimmune and inflammatory diseases.

Strategic Collaborations and Partnerships

Aerin Medical has established partnerships with leading investors such as KCK MedTech, Questa Capital, OrbiMed, Ally Bridge Group, and Ares Management Credit funds. These collaborations provide the company with financial resources and strategic guidance to support its growth initiatives.

Operational Insights

Aerin Medical differentiates itself through its commitment to providing straightforward and clinically proven products, enabling ENT physicians and their patients to make treatment decisions collaboratively. The company's focus on non-invasive, in-office procedures offers a competitive advantage in the market for chronic nasal condition treatments.

Strategic Opportunities and Future Directions

The company plans to expand its product offerings, explore new indications for its technology, and continue to build a robust clinical evidence portfolio to support the efficacy and safety of its treatments. Aerin Medical is also focused on increasing market penetration and enhancing physician and patient education to drive adoption of its products.